1. Home
  2. BL vs DMRA Comparison

BL vs DMRA Comparison

Compare BL & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackLine Inc.

BL

BlackLine Inc.

HOLD

Current Price

$29.95

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$29.55

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BL
DMRA
Founded
2001
2011
Country
United States
United States
Employees
N/A
7
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
BL
DMRA
Price
$29.95
$29.55
Analyst Decision
Buy
Buy
Analyst Count
13
2
Target Price
$56.62
$43.00
AVG Volume (30 Days)
1.3M
836.6K
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.13
N/A
Revenue
$177,031,000.00
N/A
Revenue This Year
$12.62
N/A
Revenue Next Year
$10.90
N/A
P/E Ratio
$229.85
N/A
Revenue Growth
43.78
N/A
52 Week Low
$24.70
$16.50
52 Week High
$59.57
$30.19

Technical Indicators

Market Signals
Indicator
BL
DMRA
Relative Strength Index (RSI) 57.57 70.50
Support Level $29.23 $22.71
Resistance Level $31.23 N/A
Average True Range (ATR) 1.33 2.42
MACD 0.37 0.91
Stochastic Oscillator 95.93 98.09

Price Performance

Historical Comparison
BL
DMRA

About BL BlackLine Inc.

BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: